Loading
Distinct shells carrying a filed role for this person — not every shell they have ever touched.
Of those vehicles, the ones that closed a merger.
Announced but not closed, and still hunting.
No closed vehicle here has both a stored price and a filed trust value to score it against.
1 vehicle on file, newest listing first
none appears on more than one
W. Bradford Middlekauff has served as an independent director since May 2026 and has over 32 years of experience establishing and building private and public biotechnology companies, focusing on business, governance, and legal matters. He served as integration lead and site head at Novartis from October 2025 to February 2026, Chief Business Officer and General Counsel of Tourmaline Bio, Inc. from June 2022 to October 2025, Chief Legal Officer of Castle Creek Biosciences, Inc. from May 2021 to May 2022, and General Counsel and Secretary of Immunovant, Inc. from April 2019 to November 2020. From October 2015 to April 2019, he was Senior Vice President, General Counsel and Secretary of PDS Biotechnology (formerly Edge Therapeutics, Inc.). He earned a B.A. in Political Science from Brown University and a J.D. from Yale Law School.
This record is keyed to SEC CIK 0001214501 — the identifier this person files under in their own name. Every vehicle above is a filing made under that CIK, so “the same person on two shells” is a fact about an SEC identifier rather than about a name that happens to match.
Roles are the strings the filings used, in the order they were filed. Nothing on this page ranks them, infers seniority, or offers a reason why any two of these names recur — a recurrence is a count, and the filings that produced it are linked beside every row. We also hold 12 institutional-holder rows on these vehicles, under 7 distinct name strings, and none of them is counted across vehicles: that table has no CIK column, and matching holders by name would merge firms that are not the same firm.